Impact Biomedical (IBO)
$1.57
+0.08
(+5.31%)▲
Market is closed - opens 7 PM, 11 Oct 2024
Performance
- $1.42$1.61$1.57
9.55%
Downside
Day's Volatility :11.8%
Upside
2.48%
- $1.23$3.00$1.57
21.66%
Downside
52 Weeks Volatility :59.0%
Upside
47.67%
Returns
| Period | Impact Biomedical | Index (Russel 2000) |
|---|---|---|
3 Months | -44.25% | 0.0% |
6 Months | -44.25% | 0.0% |
1 Year | -44.25% | 0.0% |
3 Years | -44.25% | -20.8% |
Highlights
Market Capitalization | 17.2M |
Book Value | $2.33 |
Earnings Per Share (EPS) | -0.37 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -5.01% |
Return On Equity TTM | -15.13% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -3.6M |
Diluted Eps TTM | -0.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Impact Biomedical is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Impact Biomedical | -44.25% | -44.25% | -44.25% | -44.25% | -44.25% |
 Regeneron Pharmaceuticals, Inc. | -10.93% | 8.12% | 21.23% | 85.29% | 239.25% |
 Novo Nordisk A/s | -9.85% | -6.35% | 25.79% | 137.8% | 353.05% |
 Alnylam Pharmaceuticals, Inc. | 5.73% | 77.74% | 60.24% | 32.45% | 248.92% |
 Vertex Pharmaceuticals Incorporated | -0.6% | 17.7% | 29.79% | 160.59% | 174.92% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Impact Biomedical | NA | NA | NA | 0.0 | -0.15 | -0.05 | NA | 2.33 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.47 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Impact Biomedical | NA | NA | -44.25% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 239.25% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 353.05% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 248.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.8B | 174.92% | 32.84 | -4.74% |
Company Information
Organization | Impact Biomedical |
Industry | Miscellaneous |
Discover More
Eaton Vance Enh Eqt Inc Ii
$1.57
+5.31%
Aditxt Inc
$1.57
+5.31%
Yieldmax Tsm Option Income Strategy Etf
$1.57
+5.31%
Innovator International Dvlpd Pwr Bff Etf - August
$1.57
+5.31%
Neos Enhanced Income 1-3 Month T-bill Etf
$1.57
+5.31%
Lakeside Holding Ltd.
$1.57
+5.31%
Allianzim Us Large Cap Buffer20 Nov Etf
$1.57
+5.31%
Jpmorgan Betabuilders Emerging Markets Equity Etf
$1.57
+5.31%
Spdr Ssga Us Large Cap Low Volatility Index Etf
$1.57
+5.31%